TP53 and lung carcinoma: Considering that p53, a pivotal tumor suppressor gene, is mutated in more than 50% of human cancers, and that its status correlates closely with the clinical outcomes of cancer patients receiving chemotherapy and with the drug responsiveness of cancer cells in vitro [18], our results also broaden the potential application of P. cocos in lung cancer treatment.